Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Ketamine Clear all
Completed Phase 4 Interventional

Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

NCT04266288
View directory record Official record
Conditions
Depression, Depression Severe, Depression Acute, Depression and Suicide, Suicidal Ideation
Interventions
Ketamine, Sodium Chloride 0.9%
Drug
Lead sponsor
MercyOne Des Moines Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study

NCT03284307
View directory record Official record
Conditions
Unconsciousness, Consciousness
Interventions
Dexmedetomidine, Ketamine, Propofol, Midazolam
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 9, 2026, 1:58 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

NCT06816433
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting

NCT02303847
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lacey, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Impact of Pre-Sedation Virtual Reality Game on Post-Discharge Negative Behaviors in the Pediatric Emergency Department

NCT03980067
View directory record Official record
Conditions
Behavior, Child, Anxiety
Interventions
Virtual Reality Game
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 9, 2026, 1:58 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

NCT07504601
View directory record Official record
Conditions
Healthy Volunteers
Interventions
(2R,6R)-Hydroxynorketamine, Placebo
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Recruiting Phase 2 Interventional

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

NCT06419439
View directory record Official record
Conditions
Chronic Low Back Pain, Depression
Interventions
Ketamine hydrochloride, Minimally Enhanced Usual Care, Brief narrative intervention
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 9, 2026, 1:58 AM EDT
Terminated Phase 4 Interventional Results available

Ketamine for Pain in the Emergency Department

NCT03896230
View directory record Official record
Conditions
Acute Pain
Interventions
Ketamine Injectable Product
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 9, 2026, 1:58 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753
View directory record Official record
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery

NCT01983020
View directory record Official record
Conditions
Postoperative Pain
Interventions
Lidocaine, Ketamine, Saline
Drug · Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 9, 2026, 1:58 AM EDT
Withdrawn Phase 2 Interventional

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

NCT05945147
View directory record Official record
Conditions
Complex Regional Pain Syndromes
Interventions
Ketamine, Midazolam, Normal Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2099
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 9, 2026, 1:58 AM EDT
Not listed Not applicable Interventional

Post-op Ketamine Study

NCT03865550
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Isotonic saline, Ketamine Injectable Solution
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Enrollment
75 participants
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 9, 2026, 1:58 AM EDT
Active, not recruiting Phase 2 Interventional

Ketamine for Methamphetamine Use Disorder

NCT06496750
View directory record Official record
Conditions
Substance Use Disorders, Substance Use, Methamphetamine Abuse
Interventions
Ketamine Hydrochloride, Midazolam Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Terminated Phase 3 Interventional

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

NCT02950233
View directory record Official record
Conditions
Pain, Postoperative
Interventions
NMDA active, Steroid active, NMDA placebo, Steroid placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

NCT03539887
View directory record Official record
Conditions
Suicidal Ideation, Depression, Alcohol Abuse
Interventions
Intranasal ketamine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Results available

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

NCT01881763
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Ketamine, Methohexital
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706
View directory record Official record
Conditions
Depression, Opioid-use Disorder, Opioid Abuse
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

NCT02397889
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 9, 2026, 1:58 AM EDT
Terminated No phase listed Observational

Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)

NCT05095792
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Observational - no intervention
Other
Lead sponsor
Entheon Biomedical Corp.
Industry
Eligibility
21 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Glutamatergic Modulation of Cocaine-related Deficits

NCT01790490
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Ketamine 0.41 mg/kg, Ketamine 0.71 mg/kg, Lorazepam 2 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 52 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 9, 2026, 1:58 AM EDT